NATIONAL BREAST CANCER FOUNDATION (NBCF) OUTLINES PINK HORIZON RESEARCH STRATEGY AT BREAST CANCER FORUM Breast Cancer Awareness Month demonstrates integral role of NBCF in research and clinical support
Filmed in Brisbane, Queensland | November 2024
Associate Professor Cleola Anderiesz, Chief Executive Officer of the National Breast Cancer Foundation, leads an organisation dedicated to funding world-class breast cancer research in Australia. The Foundation has a bold vision of achieving zero deaths from breast cancer.
Every October, during Breast Cancer Awareness Month, the foundation uses this time to raise awareness about breast cancer and its impact in Australia. It also emphasises the critical need for funding breast cancer research to improve outcomes.
The National Breast Cancer Foundation collaborates with researchers, providing essential funding while also engaging them, clinicians, and consumers to establish research priorities.
Australian Health Journal met with Assoc Prof Anderiesz to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
Recently, Assoc Professor Anderiesz presented at the Public Breast Cancer Research Forum hosted by The University of Queensland and the Translational Research Institute, where she highlighted the accomplishments of the National Breast Cancer Foundation over the past 30 years. During this time, the Foundation has invested over $200 million into more than 600 research projects across Australia, supporting 1,800 researchers at 120 institutes to advance impactful breast cancer research.
Professor Anderiesz believes it is essential for all members of the breast cancer community to consistently seek opportunities to raise awareness about the disease’s impact. This awareness should extend beyond October and include efforts to inform primary care physicians and specialists. Additionally, there is a need to promote groundbreaking research and advocate for changes in policy and care to improve outcomes for individuals affected by breast cancer.
-
New Generative AI and machine learning frontier on unused patient care data
Drawing from GE’s 125-year legacy in healthcare, Amit Yadav, CEO GE HealthCare ANZ is leading efforts to integrate AI into medical imaging devices and optimise workflow efficiencies. He stresses the importance of leveraging the vast amount of untapped healthcare data, with an emphasis on automating manual processes to enhance productivity. Additionally, his focus extends to utilising AI for workflow optimisation and ensuring compliance with local regulations and standards to prioritise safety.
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
